In addition to their benefit in HER2-over-expressing metastatic breast cancer, fam-trastuzumab deruxtecan has shown remarkable results in patients with heavily pretreated, HER2 low advanced breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.